Telehealth Prescriptions: DEA Controlled Substances

For millions of Americans managing conditions like ADHD, anxiety, or opioid use disorder, the ability to receive prescriptions via a video call has been a lifeline. Since the onset of the COVID-19 pandemic, regulations were relaxed to allow doctors to prescribe controlled substances without an initial in-person visit. However, uncertainty regarding the expiration of these rules has caused significant stress for patients and providers alike. Here is the concrete status of remote prescribing regulations as we head into late 2024 and 2025.

The Latest Update: Extension Through 2025

The most critical news for patients is the recent decision by the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS). As of late 2024, these agencies released a Third Temporary Rule.

This rule officially extends the current telemedicine flexibilities through December 31, 2025.

Before this announcement, the ability to prescribe controlled substances remotely was set to expire at the end of 2024. This extension applies to:

• Existing patients: Those who have already established a relationship with a provider via telehealth.
• New patients: Individuals who start treatment via telehealth during this extension period.

This means that if you are currently receiving medications like Adderall or Xanax through a fully remote provider, your care will remain legal and accessible for another full year. You do not need to rush to find an in-person doctor immediately, although planning for the future is still wise.

Why This Matter: The Ryan Haight Act

To understand the gravity of these updates, it is necessary to look at the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Before 2020, this law strictly prohibited the prescribing of controlled substances via the internet unless the provider had conducted at least one in-person medical evaluation of the patient.

The law was originally written to combat “rogue” internet pharmacies that were fueling the opioid crisis by selling pills without legitimate medical oversight. However, when the COVID-19 Public Health Emergency (PHE) was declared in 2020, the DEA activated an exception to this act. This exception allowed authorized providers to prescribe Schedule II through V controlled substances via two-way audio-video communication.

When the official Public Health Emergency ended in May 2023, the DEA initially planned to revert to the pre-pandemic rules. This would have cut off care for thousands of patients living in “medical deserts” or those with mobility issues. The resulting outcry led to the series of temporary extensions we are seeing now.

Specific Medications Affected

The regulations specifically target “controlled substances.” These are drugs that have a recognized medical use but also carry a potential for abuse or dependence. They are categorized into “Schedules” by the DEA.

Schedule II Stimulants

This is the category causing the most concern for ADHD patients. It includes potent stimulants such as:

• Adderall (amphetamine/dextroamphetamine)
• Ritalin and Concerta (methylphenidate)
• Vyvanse (lisdexamfetamine)

Under the Ryan Haight Act, these require the strictest oversight. During the current extension period (through Dec 31, 2025), legitimate telemedicine providers can continue to prescribe these without you stepping foot in a physical office.

Schedule III-V Medications

This category includes drugs used for anxiety, insomnia, and opioid use disorder (OUD). Common examples include:

• Benzodiazepines: Xanax (alprazolam), Klonopin (clonazepam), and Ativan (lorazepam).
• OUD Treatments: Suboxone (buprenorphine).

The flexibility for prescribing buprenorphine is particularly vital. Organizations like the American Society of Addiction Medicine have argued that forcing recovering patients to travel for in-person visits creates a barrier to treatment that could lead to relapse or overdose.

The DEA’s Proposed "Permanent" Rules vs. Reality

In early 2023, the DEA proposed a permanent set of rules that were intended to take over once the emergency waivers expired. These proposed rules were much stricter than the current environment.

The 2023 Proposal included:

• Allowing only a 30-day initial supply of controlled substances via telehealth.
• Requiring an in-person visit (or a referral from a doctor who saw the patient in person) to get any refills beyond that first 30 days.

The public reaction was historic. The DEA received over 38,000 public comments, the vast majority of which opposed the restrictions. Critics argued that mental health infrastructure in the United States is already fractured. Waiting lists for in-person psychiatrists can be months long.

Because of this overwhelming feedback, the DEA acknowledged they could not finalize the rule in time. They withdrew the strict proposal to “study the comments” and work on a new framework. This delay is exactly why we are currently operating under temporary extensions. The DEA is actively trying to design a “Special Registration” process for telemedicine providers, which would allow them to operate permanently without the in-person requirement, provided they meet higher data reporting and compliance standards.

What Patients Should Do to Prepare

While the extension to December 2025 provides breathing room, it is not a permanent fix. If you rely on telehealth for controlled medications, you should take proactive steps to secure your care continuity.

1. Verify Your Provider’s Compliance: Ensure you are using a legitimate telehealth platform. reputable services like Talkiatry or Circle Medical adhere to HIPAA and state laws. Avoid websites that promise prescriptions with little to no medical evaluation, as the DEA is cracking down on “pill mills.”
2. Maintain Documentation: Keep digital copies of your diagnosis, past prescriptions, and treatment notes. If the regulations change abruptly in 2026 and you must switch to a local doctor, having your history ready will speed up the transition.
3. Attempt One In-Person Visit: If it is geographically and financially feasible, try to see your primary care physician (PCP) in person once. Ask if they are willing to provide a referral to your telehealth specialist. Under the Ryan Haight Act, a “qualifying telemedicine referral” from a doctor who has seen you in person satisfies the legal requirement. Having this on file creates a safety net.

The Conflict: Access vs. Enforcement

The core tension here is between access to healthcare and drug enforcement.

On one side, the DEA is tasked with preventing diversion. They point to the rise of aggressive social media advertising by some telehealth startups during the pandemic that may have contributed to overprescribing.

On the other side, HHS and patient advocacy groups highlight that telemedicine is often the only option for rural Americans. In many counties in the U.S., there is not a single practicing psychiatrist. Reverting to 2008 laws would effectively deny care to these populations.

The “Special Registration for Telemedicine” is the most likely long-term solution. Congress actually mandated the DEA to create this registration almost 15 years ago, but it was never implemented. The current pressure makes it highly probable that a registration system will finally be unveiled before the 2025 deadline expires.

Frequently Asked Questions

Can I get an Adderall prescription online right now? Yes. As long as you are seeing a DEA-registered provider who determines it is medically necessary, you can receive a prescription via telemedicine without an in-person visit through December 31, 2025.

Does this apply to new patients or only existing ones? The most recent Third Temporary Rule applies to both. New patients can establish care via video call and receive controlled substance prescriptions through the end of 2025.

What happens if the DEA doesn’t make a new rule by the end of 2025? If no permanent rule is finalized and no further extension is granted, the regulations would default back to the Ryan Haight Act. This would mandate an in-person visit for all controlled substance prescriptions. However, given the bipartisan support for telehealth, another extension or a permanent fix is expected before that deadline.

Are Ketamine treatments covered by this? Ketamine is a Schedule III non-narcotic substance. While it falls under the same controlled substance regulations, the off-label use of at-home Ketamine therapy has faced intense scrutiny. While technically covered by the extension, many providers are voluntarily pulling back or requiring stricter protocols due to liability concerns.